Mountain Valley MD Holdings Inc. announced that it has received approval from the Canadian Intellectual Property Office for the patent filing around its Quicksome technology. The patent approval is the first for MVMD in the Canadian marketplace to pass formal allowance stage, formally protecting the process in Canada for Preparation of Desiccated Liposomes for Use in Compressible Delivery Systems. The Company's patented Quicksome™ liposome technology utilizes an advanced two-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective oral product formats. The patented Quicksome technology is being applied across a variety of vaccine, drug and nutraceutical applications. The Company has released pre-clinical trial data on December 10, 2020, where a solubilized version of the drug Ivermectin was administered via its Quicksome™ desiccated liposome technology as compared to an existing oral Ivermectin solution. The results demonstrated the Quicksome technology was able to successfully administer Ivermectin across the mucosa, with a significant improvement in the pharmacokinetic performance compared to current oral formats. The pre-clinical data included: a 500% increase in bio availability compared to oral tablets, a TMAX (the time to reach the maximum concentration in the body) of 1 hour, a 600% increase over oral tablets, zero decline in CMAX (peak serum concentration that a drug achieves) over the entire 6-hour period investigated, and only 5% variability compared to 40% variability for oral tablets.